Cite
140 (PB-140) Poster - Real-World Comparison of Overall Survival in Female Patients with HR+/HER2- Metastatic breast cancer receiving endocrine therapy, endocrine therapy plus palbociclib, or chemotherapy.
MLA
Rizwan, U., et al. “140 (PB-140) Poster - Real-World Comparison of Overall Survival in Female Patients with HR+/HER2- Metastatic Breast Cancer Receiving Endocrine Therapy, Endocrine Therapy plus Palbociclib, or Chemotherapy.” European Journal of Cancer, vol. 200, Mar. 2024, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ejca.2024.113714.
APA
Rizwan, U., Hussain, R., & Kanagala, G. (2024). 140 (PB-140) Poster - Real-World Comparison of Overall Survival in Female Patients with HR+/HER2- Metastatic breast cancer receiving endocrine therapy, endocrine therapy plus palbociclib, or chemotherapy. European Journal of Cancer, 200, N.PAG. https://doi.org/10.1016/j.ejca.2024.113714
Chicago
Rizwan, U., R. Hussain, and G. Kanagala. 2024. “140 (PB-140) Poster - Real-World Comparison of Overall Survival in Female Patients with HR+/HER2- Metastatic Breast Cancer Receiving Endocrine Therapy, Endocrine Therapy plus Palbociclib, or Chemotherapy.” European Journal of Cancer 200 (March): N.PAG. doi:10.1016/j.ejca.2024.113714.